{
  "docId": "019de074-d3d5-753e-80c7-2426b111c999",
  "docSlug": "1ec46bbfcfe4d48ad79d6f74349ca67d",
  "documentTitle": "ATAI | Investor Conference Presentation Deck | 14 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 12,
  "pageCount": 14,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Slide 16 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d3d5-753e-80c7-2426b111c999/12",
  "deckHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999",
  "deckJsonHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999.json",
  "deckAnchorHref": "/decks/019de074-d3d5-753e-80c7-2426b111c999#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.61,
        "y": 0.31
      },
      "kind": "chart",
      "text": "Third Party Study: Non Inferiority Test (Ham-A total score)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87339acc-3ee5-435c-8be4-9f13f701858d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.6,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Completed Phase 1 Trial: Part 1 Single Ascending Dose, Part 2 Multiple Ascending Dose",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d813a49-c12d-4cf8-bd4d-187ebca29dac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.23,
        "x": 0.37,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "Etifoxine works as rapidly as lorazepam, with etifoxine continuing its effects beyond treatment. Etifoxine has a strong safety record: a review of over 14m prescriptions in France found that there were only sporadic adverse drug reaction reports.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7b4c9e8-ef08-4b76-b14d-5f11edffdbef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: HAM-A = Hamilton Anxiety Rating Scale, SD = standard deviation, qEEG = Quantitative electroencephalography, PK = Pharmacokinetics. PD = Pharmacodynamics, PoC = Proof of Concept; 1. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of September 30th, 2022. 2. Nguyen et al., “Efficacy of etifoxine compared to lorazepam monotherapy” (2006) 3. Cottin et al., “Safety profile of etifoxine: A French pharmacovigilance survey” (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbf0bc8f-2991-4c7c-8ad6-4fab42d65b5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.32,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Ownership, Product, Pharmacology, Product Features, Indications, Current Status, Intellectual Property, Highlight",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1fab234-0a22-4a64-ba38-405f80e8a54c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.06
      },
      "kind": "title",
      "text": "GRX-917 has the potential for benzodiazepine-like rapid-onset efficacy with improved safety and tolerability",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b208bdac-696a-48a9-ac1b-9c3055325f48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY: GRX-917",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37c4ea34-e112-4fab-ae46-03bd74699a5f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ba1e0f7b-f403-4ef0-a89f-e4c7c475d17a",
      "evidence": "Similar to slide 1, this slide summarizes key points about GRX-917, indicating it serves as an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}